Fondaparinux
- Generic Name
- Fondaparinux
- Brand Names
- Arixtra
- Drug Type
- Small Molecule
- Chemical Formula
- C31H53N3O49S8
- CAS Number
- 104993-28-4
- Unique Ingredient Identifier
- J177FOW5JL
- Background
Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS is thought to form the high...
- Indication
Approved for: (1) prophylaxis of VTE for up to one month post surgery in patients undergoing orthopedic surgery of the lower limbs such as hip fracture, hip replacement and knee surgery; (2) prophylaxis of VTE patients undergoing abdominal surgery who are at high risk of thromboembolic complications (e.g. patients undergoing abdominal cancer surgery); (3) tr...
- Associated Conditions
- Acute Pulmonary Embolism (PE), Deep Vein Thrombosis, Non ST Segment Elevation Myocardial Infarction (NSTEMI), ST Segment Elevation Myocardial Infarction (STEMI), Unstable Angina Pectoris, Acute, superficial, symptomatic Vein Thrombosis
- Associated Therapies
- -
Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 200
- Registration Number
- NCT01428531
Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 5
- Registration Number
- NCT01428544
Fondaparinux EU-RMP (Adherence)
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2015-04-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01406301
Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 475
- Registration Number
- NCT01390883
Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 329
- Registration Number
- NCT01390896
Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II
- Conditions
- Interventions
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 195
- Registration Number
- NCT01304238
The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery
- Conditions
- Interventions
- First Posted Date
- 2010-12-28
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 362
- Registration Number
- NCT01267305
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, China
Hemorrhage Risk Prescribed Arixtra
- Conditions
- Interventions
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 13442
- Registration Number
- NCT01064362
Retrospective Study of Patients Who Were Treated With Fondaparinux Pre-, Peri- and/or Postpartum for Prophylaxis or Treatment of Venous Thromboembolism
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2011-08-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120
- Registration Number
- NCT01004939
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
- Conditions
- Interventions
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 41
- Registration Number
- NCT00981409
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.